Aguilar-Reina J, Rey-Romero C, Ortega-Viñas M, Hernandez-Pascual A, Sayago-Mota M
Seccion de Hepatologia, Servicio de Aparato Digestivo, Sevilla, Spain.
Hepatogastroenterology. 1990 Dec;37 Suppl 2:163-5.
The relationship between the risk of ascites recurrence and the level of cancer antigen 125 (CA 125) in serum was studied in two independent groups of patients with cirrhosis of the liver. The first group included 17 patients admitted to hospital due to ascites. When the episode was resolved, diuretic treatment was suspended and the CA 125 level in serum was determined. Eight patients had CA 125 levels above 35 U/ml (200.5 +/- 152.1 U/ml) when discharged from hospital, and ascites reappeared in all these cases within 30 days. The other nine cases (25.1 +/- 17.1 U/ml) remained free of ascites (p less than 0.005). In the second group, no evidence of ascites was found in 21 patients during 28 out-patient physical examinations. At the time of the examinations, abdominal echographic studies and CA 125 measurements were carried out. In 17 examinations, ascitic fluid was not detected by echography. CA 125 levels were normal (10.8 +/- 9.1 U/ml), and none of these subjects developed ascites. Echography detected peritoneal fluid during the remaining 11 examinations and CAH 125 levels in these cases were above 35 U/ml (278 +/- 276.9) (p less than 0.001). Six of these patients developed ascites within 30 days. We conclude that CA 125 levels can predict ascites recurrence in patients with cirrhosis of the liver.
在两组独立的肝硬化患者中研究了腹水复发风险与血清癌抗原125(CA 125)水平之间的关系。第一组包括17例因腹水入院的患者。当腹水消退后,停用利尿剂治疗并测定血清CA 125水平。8例患者出院时CA 125水平高于35 U/ml(200.5±152.1 U/ml),所有这些病例在30天内腹水均复发。其他9例(25.1±17.1 U/ml)未再出现腹水(p<0.005)。在第二组中,21例患者在28次门诊体格检查期间未发现腹水迹象。在检查时,进行了腹部超声检查和CA 125测量。在17次检查中,超声未检测到腹水。CA 125水平正常(10.8±9.1 U/ml),这些受试者均未出现腹水。在其余11次检查中超声检测到腹腔积液,这些病例的CA 125水平高于35 U/ml(278±276.9)(p<0.001)。其中6例患者在30天内出现腹水。我们得出结论,CA 125水平可预测肝硬化患者腹水复发。